<DOC>
	<DOC>NCT00965731</DOC>
	<brief_summary>This is a Phase 1/2 study comparing the safety and anti-tumor activity of erlotinib alone versus erlotinib in combination with PF-02341066 in patients with advanced non-small cell lung cancer.</brief_summary>
	<brief_title>Erlotinib Is Being Studied With Or Without An Investigational Drug, PF-02341066, In Patients With Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Crizotinib</mesh_term>
	<criteria>histologically proven diagnosis of NonSmall Cell Lung Cancer (NSCLC) that is locally advanced or metastatic and of the adenocarcinoma subtype (including mixed adenosquamous histology) evident disease progression by Response Evaluation Criterion in Solid Tumors (RECIST) after at least one but no more than 2 chemotherapy regimens for advanced disease tumors must have measurable disease as per RECIST known interstitial lung disease prior treatment with an agent that is known or proposed to be active by action on EGFR tyrosine kinase or cMet/HGF (Phase 2 Portion)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Lung Neoplasms</keyword>
	<keyword>Crizotinib</keyword>
</DOC>